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Recent identiﬁcation of active brown fat reserves in adult humans has re-stimulated interest
in the role of brown adipocytes in energy homeostasis. In addition, there is accumulating
evidence to support the concept of an alteration in energy balance through acquisition
of brown fat features in traditional white fat depots. We recently described an important
role played by theTGF-β/Smad3 signaling pathway in modulating the appearance of brown
adipocytes in traditional white fat, and its implications to thermogenesis, mitochondrial
energetics, energy expenditure, and protection from diabetes and obesity. Here we review
the data supporting this phenomenon and put into perspective the promise of conversion
of white fat to a brown fat state as a potential therapeutic option for obesity and diabetes.
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The rise in the worldwide incidence of obesity and, by a tight cor-
relation, diabetes is proof that we are failing as a populace to obey
the energy balance equation. Obesity is principally characterized
by accumulation of fat in adipose tissue (Gesta et al., 2007; Park
et al., 2008). In conditions of energy excess, thewhite adipose tissue
accumulates fat in the form of triglycerides, whilst brown adipose
tissue has the potential stimulate energy expenditure by dissipa-
tion of fat to produce heat and maintain body temperature.White
fat comprises of large unilocular lipid-containing adipocytes with
few mitochondria. In contrast, brown fat comprises of small mul-
tilocular cells with abundant mitochondria. Brown adipocytes are
uniquely characterized by the expression of uncoupling protein-
1 (UCP1). Copious amount of brown fat exists in rodents and
human infants and it was considered to be non-existent in adult
humans. Recent ﬁndings that metabolically active brown fat exists
in humans (Nedergaard et al., 2007;Cypess et al., 2009; vanMarken
Lichtenbelt et al., 2009;Virtanen et al., 2009) have stimulated inter-
est concerning the therapeutic potential of augmenting brown fat
to combat metabolic diseases (Enerback, 2010; Nedergaard and
Cannon, 2010). Further, it appears that brown fat shares its devel-
opmental origin with muscle, and not white fat as it was long
presumed (Atit et al., 2006; Timmons et al., 2007). Seale et al.
(2008, 2009) provided the formal proof that brown fat is related
to skeletal muscle and further showed that the transcription fac-
tor PRDM16 determines the fate of Myf5+-precursor cells toward
brown fat lineage.
BROWN ADIPOCYTE INDUCTION IN WHITE ADIPOSE TISSUE
Brown adipocytes are also found interspersed within the white
adipose tissue, in response to chemical or hormonal stimula-
tion, environmental changes, cold exposure, and deﬁned genetic
manipulation (Langin, 2009; Lefterova and Lazar, 2009; Frontini
and Cinti, 2010). The most well studied models whereby brown
adipocytes appear in white fat are upon cold exposure or after
stimulation of the beta(3)-adrenoceptor pathways. Cold expo-
sure of mice results in expression of the brown adipocyte marker,
UCP1, in inguinal white adipose tissue (Loncar, 1991) and in
mesenteric, epididymal, retroperitoneal, inguinal, and periovar-
ian adipose depots upon exposure to cold or to treatment with
a beta-adrenoceptor agonist (Cousin et al., 1992). In agreement,
beta 3-adrenoceptor knockout mice show suppressed occurrence
of brown adipocytes in white fat upon cold exposure (Jimenez
et al., 2003). In contrast, transgenic mice overexpressing the beta
1-adrenergic receptor in adipose tissue exhibit abundant appear-
ance of brown fat cells in subcutaneous white adipose tissue and
are resistant to obesity (Soloveva et al., 1997). Chronic treat-
ment with the beta3-adrenoceptor agonist, CL 316,243, (Bloom
et al., 1992), promotes thermogenesis, and the appearance of mul-
tilocular adipocytes in white fat while protecting from high-fat
diet-induced obesity (Himms-Hagen et al., 1994). Infusion of CL
316,243 reduced abdominal fat, increased resting metabolic rate,
and abundant multilocular brown adipocytes expressing uncou-
pling protein (UCP) appeared in retroperitoneal white fat (Ghor-
bani et al., 1997). Similarly, appearance of brown adipocytes in
white adipose tissue during CL 316,243-treatment correlated with
reversal of obesity and diabetes in Zucker fa/fa rats (Ghorbani and
Himms-Hagen, 1997). Also, beta3-adrenergic receptors mediate
CL 316,243 agonist-induced effects on energy expenditure, insulin
secretion, and food intake (Grujic et al., 1997).
Interestingly, genetic backgroundmodulates the relative degree
of browning of white adipose tissue. CL 316,243 prevented the
development of diet-induced obesity in A/J animals, but not in
C57BL/6J animals. In agreement, CL 316,243-treated A/J mice,
but not B/6J mice, showed abundant UCP1 expression in white
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adipose depots (Collins et al., 1997). Also, signiﬁcant stain-speciﬁc
differences in UCP1 transcript levels were seen in various white
fat depots derived from A/J and C57BL/6J strains of mice after
stimulation of adrenergic signaling (Guerra et al., 1998). Further,
cold exposure induced brown adipocytes in retroperitoneal fat of
adult A/J mice but not in C57BL/6J mice. In contrast, induction
of UCP1 in interscapular brown adipose tissue showed no such
strain dependence (Xue et al., 2007).
POSSIBLE MECHANISMS OF BROWNING IN WHITE FAT
TRANSDIFFERENTIATION
Tissue plasticity which allows efﬁcient conversion of white
adipocyte to brown adipocyte and vice versa has been pro-
posed as a potential mechanism (Frontini and Cinti, 2010).
Thus, cold exposure conditions would promote white-to-brown
conversion to fulﬁll the demand for thermogenesis, whereas,
high-fat diet would promote conversion of brown-to-white fat
to enable energy storage (Cinti, 2011). It is believed that mul-
tilocular fat cells that appear in white fat upon CL 316243-
treatment derive from convertible unilocular adipocytes that
become multilocular (Himms-Hagen et al., 2000) and that emer-
gence of brown adipocytes in white fat upon cold exposure
reﬂects beta(3)-adrenoceptor-mediated transdifferentiation (Bar-
batelli et al., 2010). The retinoblastoma (Rb) protein family acts
as a molecular switch determining white versus brown adipocyte
differentiation. Thus, inactivation of pRB results in the expres-
sion of UCP1 in the white adipose tissue and down-regulation
of pRB expression is associated with white into brown adipocyte
transdifferentiation in response to beta3-adrenergic receptor ago-
nist treatment (Hansen et al., 2004). Further, mice lacking the
Rb-family member, p107, possess white adipose tissue with mul-
tilocular adipocytes that express elevated levels of UCP1 and
PGC-1α, a transcriptional co-activator implicated in mitochon-
drial biogenesis and adaptive thermogenesis and pRb binds and
represses PGC-1α transcription (Scime et al., 2005).
PRECURSOR POOL ORIGIN
Multilocular fat cells that appear in white fat upon CL 316243-
treatment may derive from a precursor cell that gives rise to
more typical brown adipocytes (Himms-Hagen et al., 2000). To
date, such a precursor pool is unidentiﬁed. The evidence that
the dermis, muscle, and brown fat all originate from the central
dermomyotome (Atit et al., 2006) and that immature undifferenti-
ated brown fat cells harbor muscle-speciﬁc transcripts and brown
preadipocytes exhibit amyogenic signature (Timmons et al., 2007)
stimulated a search for a common brown fat/muscle progenitor.
Indeed, Seale et al. (2008, 2009) provided evidence that brown fat
shares developmental ontogenywith skeletalmuscle with the tran-
scription factor PRDM16 promoting the differentiation of skeletal
muscle-derived Myf5+ precursor cells toward a classical brown
adipocyte lineage. However, they did not detect Myf5+ precursor
cell derivatives in the examined white fat. These ﬁndings suggest
that, either (i) Myf5+ precursor cells do not promote the brown-
ing phenomenon in white fat, or (ii) a context dependent role
for Myf5+ precursor cells may yet exist with respect to induction
of brown adipocytes in white fat, or (iii) other distinct precur-
sor cell pools resident in white fat or other tissue/s may drive the
browning phenotype in white fat. Lineage tracing methods with
the availability of unique gene expression markers for the three
major types of adipose tissue depots – the brown (Zic1), the beige,
or brite (Hoxc9),and thewhite (Tcf21;Walden et al., 2011) –would
help identify the potential precursor pool that drives browning of
white fat.
AUTOCRINE OR PARACRINE FACTORS
Autocrine or paracrine factors – classic examples being insulin
and leptin – play critical roles in regulating not only the cells from
which they derive, but also play overarching roles in regulating the
biology of other cells that orchestrate glucose homeostasis. This is
possible via these factors engaging their speciﬁc receptors in the
cell type where the action is elicited. Several facts support a notion
that a similar such secretagogue might regulate the appearance of
brown adipocytes in white fat: (i) the white fat is a reservoir that
synthesizes and secretes multiple cytokines and hormones such
as leptin, (ii) classical brown fat might produce factors that pro-
mote brown adipocyte induction locally as well as at a distance
in white fat, and (iii) considering the muscle-speciﬁc origin of
brown adipocytes, it is logical to assume that a muscle-speciﬁc
factor might serve as a inducer of brown adipocytes. Indeed, a
muscle-derived hormone, irisin, has been identiﬁed that promotes
induction of brown adipocytes in white fat (Bostrom et al., 2012).
Irisin, whose receptor is presently unidentiﬁed, is induced in the
muscle by PGC-1α expression. It is inducedwith exercise and a rise
in plasma irisin levels correlate with increased energy expenditure,
enhanced glucose homeostasis, and protection from obesity. The
observation that irisin has paracrine effects on white fat to stim-
ulate induction of a brown fat program has utility in not only
furthering the knowledge about browning of white fat but also
has obvious therapeutic potential. It is plausible that other factors
such as irisin, produced locally in white fat or acting in a paracrine
manner, may stimulate the browning of white fat.
Neural circuits
Neural circuits are also recognized as criticalmodiﬁers of thewhite
fat to brown fat phenomenon. An enriched environment induced
browning of white fat associated with expression of genes involved
in brown adipogenesis, thermogenesis, and beta-adrenergic sig-
naling pathways along with improved energy homeostasis and
glucose tolerance (Cao et al., 2011). Hypothalamic overexpres-
sion of the brain-derived neurotrophic factor (BDNF) promoted
a lean phenotype accompanied with acquisition of brown fat
features in the white fat, whereas, inhibition of BDNF signaling
reversed this phenotype (Cao et al., 2011). Also, hypothalamic
neuropeptide Y (NPY) has been implicated in promoting brown
fat features in white fat (Chao et al., 2011). Knockdown of NPY
expression in the dorsomedial hypothalamus (DMH) reduced
white fat depots, increased energy expenditure, and suppressed
high-fat diet-inducedobesity. Interestingly, these phenomenawere
accompanied by appearance of brown adipocytes in inguinal white
adipose tissue (Chao et al., 2011).
Signaling pathways
Increased FOXC2 expression in adipocytes results in a lean
phenotype and protects from hypertriglyceridemia and diet-
induced insulin resistance and obesity primarily by increasing the
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beta-adrenergic–cAMP–protein kinase A (PKA) signaling path-
way (Cederberg et al., 2001). PPARα stimulated the expression of
the PRDM16 gene in brown adipocytes and PPARα activation in
white adipocytes induced expression of brown fat markers (Hon-
dares et al., 2011). C/EBPα and the corepressors CtBP1 and CtBP2
repress visceral white adipose genes and activate UCP1 transcrip-
tion during PPARγ agonist-mediated induction of the brown
phenotype in white adipocytes (Vernochet et al., 2009). Induc-
tion of UCP1 expression in white adipose tissue, but not in classic
interscapular brown adipose tissue, is dependent on cyclooxyge-
nase activity (Madsen et al., 2010). Cyclooxygenase (COX)-2, a
rate-limiting enzyme in prostaglandin synthesis, is a downstream
effector of beta-adrenergic signaling in white adipose tissue and
is required for appearance of brown fat features in white fat.
Prostaglandin induced differentiation of mesenchymal progen-
itors toward a brown adipocyte phenotype and overexpression
of COX-2 in white fat induced brown adipogenesis in white fat,
increased energy expenditure, and protected mice against high-
fat diet-induced obesity (Vegiopoulos et al., 2010). Retinoic acid
reduces body weight, increases body temperature and adiposity in
rodent models and stimulates UCP1 expression in brown adipose
tissue and skeletalmuscle.Administration of all-trans retinoic acid
results in reduced adiposity and adipocyte cell size with a rise in
multilocular adipocytes expressing brown fat markers in white
fat depots (Mercader et al., 2006). Wnt10b blocks beta3-agonist-
inducedbrownadipose tissuedifferentiation and suppressesUCP1
expression through repression of PGC-1α, while promoting the
appearance of unilocular lipid droplets and expression of white
adipocyte genes consistent with conversion of brown fat to white
fat (Kang et al., 2005).AMP-kinase (AMPK) signaling is also impli-
cated in the brown fat to white fat conversion. Adipose-speciﬁc
ablation of an AMP-kinase substrate, desnutrin/ATGL, converts
brown fat to a white fat-like tissue where the mice exhibit severely
impaired thermogenesis, increased expression of white fat genes
and decreased brown fat genes (Ahmadian et al., 2011).
While it is clear that many signals can promote the browning
of white fat, the mechanistic details are poorly understood. Fur-
ther, some of the prior observations utilized cell culture models
like primary mouse embryonic ﬁbroblasts differentiated fat cells
that harbor both lineages of “brown” fat cells. Also, many of the
mouse studies were not performed at thermo-neutral tempera-
ture, and instead at an adapted colder temperature of 22–24˚C
which complicates the role of these molecules in thermogenesis
and energy expenditure. Further, whether the repressing of white
fat phenotype of these molecules is executed via functional regu-
lation of adaptive thermogenesis or determination of cell fate and
it remains unclear how many of these signals regulate the Myf5+
lineage brown fat.
TGF-β SIGNALING REGULATES APPEARANCE OF BROWN
ADIPOCYTES IN WHITE ADIPOSE TISSUE
We recently elucidated the importance of TGF-β signaling in the
appearance of brown adipocytes within the white adipose tissue
(Crunkhorn, 2011; Yadav et al., 2011). The TGF-β superfamily
member,BMP7,has been implicated in brownadipogenesis (Tseng
et al., 2008). Whether, there exists cross-talk between TGF-β and
BMP signaling in mediating brown adipogenesis remains to be
determined. Similarly, whether BMP signals, or signals emanating
from other TGF-β superfamily members, play a role in promot-
ing browning of white fat remains unclear. Moreover, it is also
not known if there exists a region-speciﬁc importance of TGF-β
signaling as it pertains to brown adipocyte development within
the different white fat depots, such as the mesenteric, epididymal,
retroperitoneal, inguinal, and periovarian adipose depots.
BMP proteins promote differentiation to either white
adipocytes or brown adipocytes (Schulz et al., 2011). BMP7 trig-
gers commitment of mesenchymal progenitor cells to a brown
adipocyte lineage, and implantation of these cells into nude mice
results in development of adipose tissue containing mostly brown
adipocytes (Tseng et al., 2008). Subpopulation of adipogenic prog-
enitors (termed ScaPCs) residing in murine brown fat, white fat,
and skeletal muscle were isolated and it was shown that muscle
and white fat derived Sca-1(+) cells were able to differentiate into
brown-like adipocytes upon stimulation with BMP7 (Schulz et al.,
2011). Also, Bmp7 knockout embryos show amarked reduction of
brown fat, whereas, adenoviral-mediated expression of BMP7 in
mice results in a signiﬁcant increase in brown fat mass and leads
to an increase in energy expenditure and a reduction in weight
gain (Tseng et al., 2008). However, the role of BMP7 in promoting
browning of white fat remains unclear. A more recent study iden-
tiﬁed Zfp423, a BMP-Smad signaling effector, as a transcriptional
regulator of both brown and white preadipocyte differentiation
(Gupta et al., 2010), although whether Zfp423 plays a role in
promoting brown fat features in white fat is unknown.
The molecular signature that we obtain in white fat derived
from Smad3-deﬁcient mice and mice treated with the TGF-β neu-
tralization antibody, 1D11, provides interesting insight into the
development of brown adipocytes within the white fat milieu.
Thus, white fat from Smad3−/− mice and mice treated with
1D11 antibodies, expresses a preponderance of genes that repre-
sent brown fat, mitochondrial, and skeletal muscle biology (Yadav
et al., 2011). These ﬁndings are in contrast to studies where PPAR
γ agonist rosiglitazone promotes norepinephrine augmentable
UCP1 gene expression in a subset of white adipocyte cells, with-
out concurrent expression of brown fat/muscle-speciﬁc markers
(Petrovic et al., 2010). Thus, chronic treatment with rosiglitazone
promotes the expression of brown fat genes, mitochondriogen-
esis, and thermogenesis capacity in a signiﬁcant subset of white
fat cells. However, the cells, referred to as “brite” adipocytes, are
devoid of transcripts for classic brown adipocytesmarkers (includ-
ing PRDM16) or for myocyte-associated genes.We reconcile these
observations as evidence of at least two separate pathways that
promote browning in the white fat. Rosiglitazone might promote
a pool of brown adipocyte precursors that does not share a mus-
cle origin, while the TGFβ1 effect could act on a pool of cells
that might potentially represent a common progenitor for white,
brown, and muscle cells. Smad3 cooccupies the genome with cell
type speciﬁc master transcription factors, including Myod1 in
myotubes, PU.1 in pro-B cells, and Oct4 in ESCs (Mullen et al.,
2011). It is conceivable that in white fat cells, Smad2/3 interacts
with factor/s that specify and maintain cell identity and cellu-
lar function. This would also provide plausible explanation for
the increased expression of brown fat and skeletal muscle-speciﬁc
genes in Smad3−/− white fat.
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THERAPEUTIC RELEVANCE
Discovering approaches to either prevent fat storage or promote
fat dissipationwill have amajor clinical impact (Tseng et al., 2010).
Human white adipocytes have the potential to acquire brown fat
cell features (Tiraby et al., 2003). Our ﬁndings support the notion
that promoting brown adipocyte like features in white fat might
favorably alter energy balance and protect from obesity and dia-
betes (Tiraby andLangin,2003). Further,our anti-TGF-β antibody
studies strongly suggest that this strategy has translational poten-
tial in treatment of human obesity and diabetes. Similarly, the role
of neuronal signaling regulators,NPY, and BDNF, have been eluci-
dated in the promotion of browning of white fat (Cao et al., 2011;
Chao et al., 2011)making these factors amenable for consideration
as therapeutic targets. Importantly, the fact that simple changes
in the environment promotes hypothalamic BDNF expression
and leads to browning of white fat and increased energy dissi-
pation (Cao et al., 2011) is of particular relevance with respect to
behavioral modulation as a means to manage and treat obesity
and diabetes. Interestingly, nicotine induces browning of white
fat, along with associated histological and molecular character-
istics, decreases food intake and protects from obesity (Yoshida
et al., 1999) thus presenting a potential anti-obesity modality.
Furthermore, evidence that prostaglandins, cyclooxygenase 2, and
retinoic acid mediated pathways promote the accumulation of
brown adipocyte like cells in traditional white fat depots (Mad-
sen et al., 2010; Vegiopoulos et al., 2010; Mercader et al., 2006)
argues for utility of these molecules and their downstream effec-
tors as candidate therapeutic targets. Finally, considering its ability
to induce browning of white fat and improving glucose home-
ostasis, the hormone irisin can now be added to list of therapeutic
candidates for metabolic disease (Bostrom et al., 2012).
As elevated TGF-β levels are common in many disease con-
ditions, there is a push to develop TGF-β antagonist therapies,
including TGF-β neutralization antibodies and small molecule
TGF-β receptor antagonists (Yingling et al., 2004). Indeed, such
regimens are being clinically evaluated for diseases, such as can-
cer, ﬁbrosis, scarring, diabetic nephropathy, where elevated TGF-β
levels are implicated (Massague et al., 2000; Rane et al., 2006;Mas-
sague, 2008). Findings that TGF-β1 levels are elevatedwith obesity,
taken together with our illustration of beneﬁcial effects of the anti-
TGFβ neutralization in mouse models of obesity and diabetes,
provide a rationale to consider anti-TGF-β modalities for these
diseases. The efﬁcacy of 1D11 (α-TGF-β) has been tested in pre-
clinical disease models (Ling et al., 2003; Nam et al., 2008) and a
closely related human version of this antibody, designated Fresoli-
mumab, is currently under evaluation in human clinical studies
of pulmonary ﬁbrosis, renal disease, and cancer. However, the
TGF-β family proteins engage speciﬁc receptors in virtually every
cell type (Roberts and Sporn, 1985). In addition to the canonical
TGF-β/Smad signaling node, cross-talk with other signaling net-
works is a common feature of TGF-β signals (Derynck and Zhang,
2003) and inhibiting the TGF-β pathway at the ligand–receptor
level may damage essential signaling networks that cross-talk with
TGF-β.
Although we propose that modulation of TGF-β/Smad3 sig-
naling activates a brown adipocyte like phenotype in rodent white
fat, its implication in browning of human white fat is unclear
at this time. Further, understanding the molecular pathways of
TGF-β/Smad3 signaling as it pertains to appearance of brown
adipocytes in white fat depots is essential to decipher mechanistic
details. Does TGF-β/Smad3 signaling affect transdifferentiation
or precursor cell dynamics as it induces browning of white fat?
Which white fat depots are the primary targets, and how do the
TGF-β/Smad3 signals harmonizewith othermolecules,hormones,
and pathways that also regulate browning of white fat? Answers to
these questions, while yielding greater mechanistic insight, will
uncover novel targets for development of rational therapeutics to
counter obesity and diabetes.
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